Therefore, we determined the association between genetic alterations in Mapk14 and clinical events (e.g., clinical stage, M-stage, and immunotherapy response) by multi-omic profiling, using large multi-omic data from the same tumor. This evidence concerns the gene MAPK14 and neoplasm.